Antios Therapeutics’ Record-Breaking Year
Please join us on Thursday, November 7, at 8:30 AM at the 21st Annual Southeast BIO Investor & Partnering Forum for breakfast and a fireside chat on building game-changing companies in the field of antiviral medicine, creativity in drug discovery, and novel models of academia-industry collaboration. Dr. Abel De La Rosa, CEO of Atlanta-based Antios Therapeutics and Gerry Brunk, Managing Director of Lumira Ventures, will hold a fireside chat to discuss the founding story of Antios, the role of creative thinking in the discovery of new drugs and lessons learned from building...
Read MoreVivex Biomedical’s Success Story Explored
Vivex Biomedical’s Success Story Explored Please join us on Thursday, November 7, at 3:00 PM at the 21st Annual Southeast BIO Investor & Partnering Forum for a fire-side chat on the emergence, funding, and growth of Vivex Biomedical with “Vivex Biomedical: Tissue-Derived Biologic Therapies.” Tom Callaway, venture partner at HealthQuest Capital, will interview the senior leadership that built this Fort Lauderdale-based success. Panelists will include Vivex Founder Tracy S. Anderson who is an Atlanta-based serial entrepreneur, John A. McCallum of private...
Read MoreBIO Alabama names director as it targets bioscience sector growth
BIO Alabama said experienced healthcare executive Sonia Robinson has joined the statewide bioscience trade association as its first full-time executive director, leading efforts within the sector to grow employment, increase research development and expand international trade. “The entire life sciences ecosystem is active in Alabama from research to institutional tech transfer; from startups and corporate innovation to global manufacturing,” said Greg Canfield, secretary of the Alabama Department of Commerce. “With this milestone, BIO Alabama is positioned to foster continued growth...
Read MoreKemPharm Announces Entry into Definitive Collaboration and License Agreement for its ADHD Candidates
CELEBRATION, FL. – KemPharm, Inc. (Nasdaq: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today announced its entry into a definitive collaboration and license agreement (the License Agreement) with an affiliate of Gurnet Point Capital (GPC), a private investment firm focused on the life sciences and medical technology sectors. The License Agreement provides for an exclusive worldwide license to develop, manufacture and commercialize KemPharm’s product candidates containing serdexmethylphenidate (SDX) and...
Read MoreADMA Biologics Announces Commercial Relaunch and its First Commercial Sales of BIVIGAM®
BOCA RATON, FL. & RAMSEY, N.J. – ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), a vertically integrated commercial biopharmaceutical and specialty immunoglobulin company that manufactures and markets three approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases, announces the commercial relaunch and its first commercial sales of BIVIGAM®. As previously reported, BIVIGAM® had a Biologics License Application (“BLA”) manufacturing change Prior Approval Supplement (“PAS”) approved...
Read MorePrecision cancer drug startup GeneCentric acquires nearby Select ImmunoGenomics
RESEARCH TRIANGLE PARK, N.C. -A couple of Research Triangle area precision medicine start-ups have decided that two technology platforms are better than one. They’re joining forces to find new ways to fight cancer. Research Triangle Park-based GeneCentric Therapeutics, Inc. announced that it has acquired Chapel Hill’s Select ImmunoGenomics, LLC. Financial terms weren’t disclosed. It’s a match that will combine informatics with immuno-therapeutics (using the body’s natural immune system to fight cancer). GeneCentric uses its proprietary genomics technology to define cancer subtypes...
Read More
Follow Us!